NATESTO Drug Patent Profile

Which patents cover Natesto, and what generic alternatives are available?

Natesto is a drug marketed by Acerus and is included in one NDA. There are two patents protecting this drug.

This drug has two patent family members in one country.

The generic ingredient in NATESTO is testosterone. There are sixty-nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Natesto

A generic version of NATESTO was approved as testosterone by ACTAVIS LABS UT INC on January 27^th, 2006.

Summary for NATESTO

International Patents:	2
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	9
Drug Prices:	Drug price information for NATESTO
What excipients (inactive ingredients) are in NATESTO?	NATESTO excipients list
DailyMed Link:	NATESTO at DailyMed

See drug prices for NATESTO

Recent Clinical Trials for NATESTO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Southern California College of Optometry at Marshall B. Ketchum University	Phase 2
Acerus Pharmaceutical	Phase 4
University of Florida	Phase 4

See all NATESTO clinical trials

Pharmacology for NATESTO

Drug Class	Androgen
Mechanism of Action	Androgen Receptor Agonists

US Patents and Regulatory Information for NATESTO

NATESTO is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acerus	NATESTO	testosterone	GEL, METERED;NASAL	205488-001	May 28, 2014		RX	Yes	Yes	11,744,838
Acerus	NATESTO	testosterone	GEL, METERED;NASAL	205488-001	May 28, 2014		RX	Yes	Yes	11,090,312

Expired US Patents for NATESTO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Acerus	NATESTO	testosterone	GEL, METERED;NASAL	205488-001	May 28, 2014	8,574,622
Acerus	NATESTO	testosterone	GEL, METERED;NASAL	205488-001	May 28, 2014	8,784,882
Acerus	NATESTO	testosterone	GEL, METERED;NASAL	205488-001	May 28, 2014	8,877,230
Acerus	NATESTO	testosterone	GEL, METERED;NASAL	205488-001	May 28, 2014	8,784,869

EU/EMA Drug Approvals for NATESTO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Warner Chilcott UK Ltd.	Intrinsa	testosterone	EMEA/H/C/000634Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28
Warner Chilcott  Deutschland GmbH	Livensa	testosterone	EMEA/H/C/000630Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.	Withdrawn	no	no	no	2006-07-28

International Patents for NATESTO

See the table below for patents covering NATESTO around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2014080282
World Intellectual Property Organization (WIPO)	2014080283
World Intellectual Property Organization (WIPO)	2014080283
Argentina	047722	SISTEMA DE TRANFERENCIA DE LIBERACION CONTROLADA PARA APLICACIONES NASALES
Austria	E319426

Last updated: July 25, 2026

NATESTO (INTRANASAL NALLKSONE?) Market Dynamics and Financial Trajectory: Sales Drivers, Exclusivity, Competition, and Revenue Risk

NATESTO is a testosterone nasal spray by Lipocine Inc. The product’s financial trajectory is tied to: (i) the pace of adoption in hypogonadism, (ii) payer coverage and formulary access for intranasal testosterone versus injectables and gels, (iii) channel inventory and pricing actions, and (iv) exclusivity and generic/biosimilar entry risk tied to the Orange Book and listed patents.

Market dynamics in the current phase are dominated by category competition and payer scrutiny. Intranasal delivery is a differentiator versus transdermal gels but faces head-to-head pricing pressure and substitution toward lowest acquisition cost where formularies tighten.

Financial trajectory is shaped by commercialization scale, commercial spend discipline, and changes in net sales from wholesaler demand. For investors and licensors, the key risk is whether NATESTO sustains volume growth after early uptake, while maintaining gross margin under increased discounting and patient access headwinds.

---

What is NATESTO’s commercial profile in hypogonadism and how big is the addressable market?

NATESTO indication and positioning

NATESTO (testosterone nasal solution) is marketed for treatment of adult men with hypogonadism, with low testosterone levels and clinical symptoms. In market terms, it sits in the broader “testosterone replacement therapy” (TRT) category where prescribers choose among:

• Transdermal gels and solutions (often first-line via payer preference)
• Intramuscular and subcutaneous injectables (often formulary-favored by cost)
• Buccal systems, pellets, and other modalities
• Intranasal testosterone (NATESTO’s differentiator)

Category pull: why TRT remains structurally resilient

Even when pricing compresses, TRT demand is supported by:

• A large diagnosed base in primary care and endocrinology
• Ongoing patient identification and prescribing in aging populations
• Shifts between modalities driven by adherence and adverse event profiles

Where NATESTO competes

NATESTO’s practical competitive set is intranasal testosterone plus all “therapeutic equivalents” used to treat symptomatic hypogonadism. It competes for:

• Initial formulary acceptance (payer coverage)
• Switch volume from gels and injections
• Refill adherence in chronic therapy

---

How do payer coverage, formulary status, and reimbursement affect NATESTO sales?

Formulary access is the main near-term sales lever

TRT is frequently managed with step therapy, prior authorization, and tier placement. NATESTO’s net sales sensitivity typically comes from:

• Prior authorization requirements tied to baseline testosterone and symptoms
• Quantity limits and refill timing rules
• State Medicaid and managed care formularies, which can swing demand with plan changes

Channel pressure and net price

Retail substitution is less relevant than pharmacy benefit design. Wholesale orders can be volatile when:

• Payers re-tier products
• PBMs refresh formularies
• Competitors run pricing programs or contracts

What to watch in financial reporting

For sales trajectory, the operational KPIs to monitor in company disclosures include:

• Net sales trends by quarter and seasonal ordering patterns
• Gross margin and whether discounts expand faster than volume
• Gross-to-net changes, especially if contract intensity increases
• Inventory levels and whether wholesaler demand is accelerating or normalizing

---

What are the main market dynamics driving intranasal testosterone adoption?

Adherence and patient preference

Intranasal delivery can improve adherence for patients who:

• Dislike daily gel application or risk skin transfer
• Prefer less clinic-dependent dosing than injectables

Prescriber behavior

Adoption depends on:

• Clinician familiarity with dosing, titration, and monitoring
• Perceived tolerability and consistency of dosing compared with gels/injectables
• Safety monitoring logistics and real-world experience

Real-world tolerability

Intranasal formulations carry unique considerations for:

• Nasal congestion, irritation, and compliance with administration technique
• Dose consistency and “missed dose” behavior These can influence persistence and refill rates, which drive revenue durability.

---

How strong is NATESTO’s patent and exclusivity position for preventing generic competition?

What patents protect NATESTO?

NATESTO is protected by a patent estate that typically includes:

• Composition and formulation patents
• Method-of-use patents tied to administration for testosterone replacement
• Patents covering manufacturing and stability for the intranasal product
• Supplementary patents from line extensions, if pursued

What is the Orange Book status of NATESTO?

Key commercial significance: Orange Book listings determine whether applicants seeking generic versions can file Paragraph IV challenges, and they establish the listed patent framework that can delay approval.

When does NATESTO lose exclusivity?

Exclusivity and patent expiration timelines determine when generic entry becomes feasible and when exclusivity-driven settlement leverage exists. For market planning, the critical date set is:

• Regulatory exclusivity expiry (if applicable)
• Latest listed patent expiration date for Orange Book-protected claims
• Any pediatric exclusivity extensions (if awarded)
• Any settlement-triggered “launch timing” commitments

These timelines are the primary gating factor for the next step-function revenue risk. Absent a precise Orange Book date set in the current record, the commercial guidance is: market forecasts must model a revenue step-down scenario if the final listed patent window ends and generic entry accelerates.

---

What patent litigation affects NATESTO and what generic entry risks exist?

Paragraph IV challenge pathway

If challengers file under Paragraph IV, the likely market outcomes are:

• 180-day exclusivity for the first filer (if upheld)
• Settlement agreements that delay launch
• Court outcomes that shape whether additional filers enter early

Financial trajectory sensitivity

Revenue sensitivity is driven by:

• Time from patent expiry to actual commercial launch
• How quickly payers switch coverage
• Whether NATESTO retains any differentiated status or is forced into price competition

Biosimilar risk

NATESTO is a small-molecule testosterone product, not a biologic. Biosimilar frameworks do not apply. The generic framework is the relevant competition vector.

---

How do NATESTO competitors compare on access, price, and utilization?

Therapeutic modality comparison

NATESTO competes across modalities with distinct payer and prescriber dynamics:

• Gels and solutions often win initial formulary placement due to ease of prescribing and familiar monitoring patterns.
• Injectables are frequently priced and reimbursed aggressively, with payer step therapy common.
• Intranasal has a narrower usage base but can win switch cases where patients prefer it.

Competitive pricing and contract intensity

When managed care tightens, net prices converge toward the lowest acquisition cost option. That is a structural headwind for smaller-market entrants unless differentiation translates into payer preference.

---

How does NATESTO pricing and discounting affect gross margin and long-term profitability?

Gross margin is the second main lever

Even with stable volume, gross margin can deteriorate if:

• Wholesale distributors negotiate larger rebates
• PBM contracts add discount pressure
• Competitors force price reductions for market share

Operating leverage matters

For small-cap biopharma, operating cost structure influences whether the company can sustain commercialization spend while:

• Investing in payer and formulary contracting
• Expanding patient support and reimbursement services
• Maintaining sales force productivity

Net sales quality

The “quality” of sales is judged by how much gross-to-net rises. High gross-to-net can indicate:

• Heavy rebate and contracting
• Greater payer pushback against intranasal dosing value

---

What do financial results imply about NATESTO’s trajectory: growth, stabilization, or decline?

Trajectory drivers

Financial trajectory for NATESTO typically depends on whether the following vectors are improving:

• Prescriber adoption (new scripts)
• Persistence (refills and continuity)
• Payer access stability (fewer coverage losses)
• Product availability (reducing stock-outs or supply constraints)
• Marketing effectiveness (incremental prescriptions versus churn)

Common inflection patterns in TRT commercialization

TRT products often show:

• Early adoption ramp with incremental share gains
• A plateau once formularies are set and prescribers stop trying alternatives
• A decline risk if pricing and coverage worsen or if a generic competitor enters

Modeling approach for revenue planning

For business planning, forecasts should separate:

• Base demand from maintenance prescriptions
• Switch demand from gels/injectables
• Step-down demand from coverage loss or generic entry

---

What commercialization and regulatory events can change NATESTO’s market outlook quickly?

Labeling and safety communications

Any FDA label update that affects:

• Indication scope
• Contraindications and warnings
• Dosing guidance can quickly change utilization and payer coverage.

Manufacturing or supply

Supply constraints disrupt continuity and refill rates, leading to lost revenue that can be slow to recover.

Commercial contracts

Large payer contracts, PBM formularies, and national account agreements can move demand in discrete steps across quarters.

---

Key Takeaways

• NATESTO’s market dynamics are dominated by payer formulary access, gross-to-net pressure, and substitution across TRT modalities.
• The financial trajectory hinges on whether intranasal adoption sustains switch volume and persistence, not only initial uptake.
• The largest structural revenue risk is generic entry timing governed by Orange Book-listed patents and any Paragraph IV litigation outcomes.
• Generic risk is the primary modeled competitive vector; biosimilar risk does not apply to testosterone small-molecule products.

---

FAQs

1) What factors determine whether NATESTO maintains formulary preference versus gels and injectables?
Payer step therapy rules, prior authorization criteria, PBM tier placement, and net price through rebates drive formulary preference.

2) How should NATESTO revenue be forecasted across quarters?
Separate baseline persistence demand from switch demand, then apply coverage-change shocks and any launch timing assumptions tied to patent expiry.

3) What does “gross-to-net” reveal about NATESTO commercialization intensity?
Rising gross-to-net typically signals stronger payer contracting pressure, discounting, or expansion of rebate obligations.

4) What is the most likely competitive timeline risk for NATESTO?
The end of the latest Orange Book patent and any settlement-limiting constraints, which can enable generic launch and rapid payer substitution.

5) Do biosimilars affect NATESTO market share?
No. NATESTO is a small-molecule testosterone product; biosimilar frameworks do not govern competition.

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm